Sanofi Extends, Revamps Discovery Pact With Warp Drive
This article was originally published in Scrip
Sanofi SA has extended and revamped its existing discovery pact with Warp Drive Bio - a move that increases chances the French group will buy the Boston-based biotech if they successfully use its two computational platforms to find new oncology drugs and antibiotics based on natural products.
You may also be interested in...
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions...
France’s Provepharm Life Solutions, which finds new uses for known mature molecules, in particular antidotes and surgical dyes, by improving their efficacy and maximizing their therapeutic potential, has fresh funds to expand its portfolio.
Provention has been working hard collecting necessary data for a potential BLA resubmission for teplizumab in patients at risk of developing type 1 diabetes after receiving a complete response letter in July. Hopes rest on a Type A meeting with the FDA in Q4.